

DAFTAR PUSTAKA

Bebelman, M.P., Smit, M.J., Pegtel, D.M., dan Baglio, R., 2018, *Pharmacology & Therapeutics Biogenesis and function of extracellular vesicles in cancer*, *Pharmacology and Therapeutics*, 188, pp. 1–11. doi: 10.1016/j.pharmthera.2018.02.013.

Brien, J.O., Hayder, H., Zayed Y., dan Peng, C, 2018, *Overview of MicroRNA Biogenesis , Mechanisms of Actions , and Circulation*, *Frontiers in Endocrinology*, 9(402), pp. 1–12. doi: 10.3389/fendo.2018.00402.

Dall’Era, M.A., Albertsen, P.C., Bangma, C., Carroll, P.R., Carter, H.B., Cooperberg, M.R., Freedland, S.J., Klotz, L.H., Parker, C., dan Soloway, M.S., 2012, *Active Surveillance for Prostate Cancer: A Systematic Review of the Literature*, *European Urology*, 62(6), pp. 976–983. doi: <https://doi.org/10.1016/j.eururo.2012.05.072>.

Exiqon, 2016, *miRCURYTM Exosome Isolation Kit - Cells , urine and CSF*, pp. 1–18.

Exiqon, 2016, *miRCURY LNATM Universal RT microRNA PCR*

Fang, Y.X., dan Gao, W.Q., 2013, *Roles of microRNAs during prostatic tumorigenesis and tumor progression*, *Oncogene*. Macmillan Publishers Limited, 33, pp. 135. <https://doi.org/10.1038/onc.2013.54>.

Feng, Y.H., dan Tsao, C.J., 2016, *Emerging Role of microRNA-21 in Cancer (Review)*, *Biomedical Reports*, 5(4), pp. 395–402. doi: <https://doi.org/10.3892/br.2016.747>.

Folini, M., Gandellini, P., Longoni, N., Profumo, V., Callari, M., Pennati, M., Colecchia, M., Supino, R., Veneroni, S., Salvioni, R., Valdagni, R., Daidone, M.G., dan Zaffaroni, N., 2010, *miR-21 : an oncomir on strike in prostate cancer*, *Molecular Cancer*, 9(12), pp. 1–12. doi: 10.1186/1476-4598-9-12.

Ikatan Ahli Urologi Indonesia, 2015, *Panduan Penatalaksanaan Klinis Pembesaran Prostat Jinak (Benign Prostatic Hyperplasia/BPH)*.

Ingle, S., Ingle, R., dan Suresh, 2013, *The Efficiency of the Serum Prostate Specific Antigen Levels in Diagnosing Prostatic Enlargements*, *Journal of Clinical and Diagnostic Research*, 7(1), pp. 82–84. doi: 10.7860/JCDR/2012/4926.2676.

Kementrian Kesehatan Republik Indonesia, 2014, *Panduan Penatalaksanaan Kanker Prostat*.

Kementrian Kesehatan Republik Indonesia, 2016, *Profil Kesehatan Indonesia*.

Kresno, S.B., 2011, *Micro-RNA dan Implikasinya pada Kanker*, *Indonesian Journal of Cancer*, 5(3), pp. 119–127.

Kristanto, J., 2017, *Ekspresi Hsa miR-21-5p pada sampel urin kanker prostat dan benign prostatic hiperplasia (BPH)*, Universitas Gadjah Mada, pp. 1–7.

Kumarswamy, R., Volkman, I., dan Thum, T., 2011, *Regulation and function of miRNA-21 in health and disease*, *RNA biology*, 8(5), pp. 706–713. doi: 10.4161/rna.8.5.16154.

Kumar, B., Rosenberg, A.Z., Choi, S.M., Fox-Talbot, K., De Marzo, A.M., Nonn, L., Brennen W.N., Marchionni, L., Halushka, M.K., dan Lupold, S.E., 2018, *Cell-type Specific Expression of Oncogenic and Tumor Suppressive microRNAs in the Human Prostate and Prostate Cancer*, *Scientific Reports*, 8(1), pp.7189. doi: 10.1038/s41598-018-25320-z.

Lange, T., Stracke, S., Rettig, R., Lendeckel, U., Kuhn, J., Schluter, R., Rippe, V., Endlich, K., dan Endlich, N., 2017, *Identification of miR-16 as an endogenous reference gene for the normalization of urinary exosomal miRNA expression data from CKD patients*, *PLoS ONE*, 12(8), pp. 1–13. <https://doi.org/10.1371/journal.pone.0183435>

Livak, K.J., dan Schmittgen, T.D., 2001, *Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the $2^{-\Delta\Delta Cq}$ Method*, 408, pp. 402–408. doi: 10.1006/meth.2001.1262.

Macfarlane, L., dan Murphy, P.R., 2010, *MicroRNA : Biogenesis , Function and Role in Cancer*, *Current Genomics*, 11(7), pp. 537–561. doi: 10.2174/138920210793175895

Melbø-jørgensen, C.N., 2012, *The expression of miR-21 in prostate cancer measured by in situ hybridization and its relevance as a diagnostic biomarker*, *University of Tromsø UIT*, pp. 1–40.

Nogueira, L., Corradi, R., dan Eastham, J.A., 2009, *Prostatic Specific Antigen for Prostate Cancer Detection*, *International Brazilian Journal of Urology*, 35(5), pp.521 – 531.

Nolan, T., Huggett, J., dan Sanchez, E., 2013, *Good practice guide for the application of quantitative PCR (qPCR)*, LGC.

Porzycki, P., Ciszkowicz, E., dan Tyrka, M., 2018, *Combination of Three miRNA (miR-141, miR-21, and miR-375) as potential diagnostic tool for prostate cancer recognition*, *International Urology and Nephrology*, Springer Netherlands, 50(9), pp. 1619–1626. doi: 10.1007/s11255-018-1938-2.

Prcic, A., Begic, E., dan Hiros, M., 2016, *Usefulness of Total PSA Value in Prostate Diseases Diagnosis*, *Acta Informatica Medica*, 24(3), pp. 156–161. doi: 10.5455/aim.2016.24.156-161.

Roehrborn, C.G., 2008, *The utility of serum prostatic-specific antigen in the management of men with benign prostatic hyperplasia*, *International Journal of Impotence Research*, 20, pp. S19 – S26. doi: 10.1038/ijir.2008.53.

Selcuklu, S.D., Donoghue, M.T.A., dan Spillane, C.. 2009, *miR-21 as a key regulator of oncogenic processes*, *Biochemical Society Transactions*, 37(4), pp. 918–925. doi: 10.1042/BST0370918.

Sohel, M.H., 2016, *Achievements in the Life Sciences Extracellular / Circulating MicroRNAs : Release Mechanisms , Functions and Challenges, Achievement in the Life Sciences*, 10(2), pp. 175–186. doi: 10.1016/j.als.2016.11.007.

Velcheti, V., Karnik, S., Bardot, S.F., dan Prakash, O., 2008, *Pathogenesis of Prostate Cancer : Lessons from Basic Research*, *The Ochsner Journal*, 8(4), pp. 213–218.